INmune Bio (INMB)
(Delayed Data from NSDQ)
$5.22 USD
-0.11 (-2.06%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $5.21 -0.01 (-0.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for INmune Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 36 | 52 | 75 | 22 | 7 |
Receivables | 2 | 8 | 6 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 4 | 2 | 0 | 0 |
Total Current Assets | 40 | 65 | 83 | 24 | 8 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 17 | 17 | 17 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 57 | 82 | 100 | 41 | 24 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 5 | 4 | 2 | 1 |
Current Portion Long-Term Debt | 10 | 5 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 11 | 4 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 10 | 14 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 22 | 20 | 2 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 159 | 152 | 144 | 72 | 45 |
Retained Earnings | -121 | -91 | -64 | -33 | -21 |
Other Equity | -1 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 37 | 60 | 80 | 39 | 24 |
Total Liabilities & Shareholder's Equity | 57 | 82 | 100 | 41 | 24 |
Total Common Equity | 37 | 60 | 80 | 39 | 24 |
Shares Outstanding | 18.00 | 17.90 | 17.80 | 13.40 | 10.70 |
Book Value Per Share | 2.07 | 3.36 | 4.51 | 2.89 | 2.21 |
Fiscal Year End for INmune Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 31 | 26 | 36 | 42 | 48 |
Receivables | 3 | 3 | 2 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 2 | 3 |
Total Current Assets | 36 | 30 | 40 | 46 | 53 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 17 | 17 | 17 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 52 | 47 | 57 | 63 | 70 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 9 | 8 | 4 | 2 |
Current Portion Long-Term Debt | 5 | 7 | 10 | 10 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 0 | 1 | 1 |
Total Current Liabilities | 15 | 17 | 18 | 14 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 2 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 2 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 19 | 20 | 19 | 19 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 179 | 161 | 159 | 157 | 155 |
Retained Earnings | -142 | -132 | -121 | -113 | -104 |
Other Equity | -1 | -1 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 36 | 28 | 37 | 44 | 51 |
Total Liabilities & Shareholder's Equity | 52 | 47 | 57 | 63 | 70 |
Total Common Equity | 36 | 28 | 37 | 44 | 51 |
Shares Outstanding | 19.70 | 18.20 | 18.00 | 18.00 | 17.90 |
Book Value Per Share | 1.84 | 1.55 | 2.07 | 2.44 | 2.83 |